

Company Description

Aeterna Zentaris Inc. (“Aeterna” or “the Company”) is a specialty biopharmaceutical company developing and commercializing novel pharmaceutical therapies to enhance and improve patient lives. Focused on establishing revenues and profitability while optimizing resources to reduce its burn rate, the Company co-promotes two commercial products in multiple U.S. markets: (1) EMD Serono’s Saizen® [somatropin (rDNA origin) for injection] for pediatric and adult growth hormone deficiencies; and (2) Armune BioScience’s Apify®, a non-PSA blood test for evaluating prostate cancer risk. Aeterna’s development program currently includes Macrilen™ (macimorelin), which has completed a confirmatory Phase 3 trial for the evaluation of Adult Growth Hormone Deficiency (AGHD), with the Company intending to file a new drug application (NDA) seeking approval for this treatment following its successful meeting with the U.S. Food and Drug Administration (FDA). Aeterna is further working to acquire or in-license other commercial products while also out-licensing Macrilen™ for non-U.S. territories. Overall, Aeterna is focused on pursuing strategic initiatives consistent with becoming a commercially operating specialty biopharmaceutical company.

Key Points

- On May 8, 2017, Aeterna announced financial and operating results for the first quarter ended March 31, 2017. Revenues were \$261,000 for the three months ended March 31, 2017 versus \$242,000 for the same period in 2016. Net loss for the three months ended March 31, 2017 was \$(4.1) million, or \$(0.31) per basic and diluted share versus a net loss of \$(3.7) million, or \$(0.37) per basic and diluted share, for the same period in 2016. The increase in net loss is largely attributable to lower operating expenses offset by lower net finance income.
- On May 1, 2017, Aeterna reported that the ZoptEC (zoptarelin doxorubicin in endometrial cancer) Phase 3 study of Zoptrex™ in women with locally advanced, recurrent, or metastatic endometrial cancer did not achieve its primary endpoint of demonstrating a statistically significant increase in the median period of overall survival of patients treated with Zoptrex™ when compared to patients treated with doxorubicin. Therefore, results of the study did not support regulatory approval of Zoptrex™. Based on this outcome, the Company announced that it did not anticipate conducting clinical trials with respect to any other indications of Zoptrex™.
- On the heels of this news, Aeterna is now completely focused on filing its new drug application (NDA) for Macrilen™ and, should the product be approved, would look to have its commercial launch as soon as possible following regulatory approval. The Company further announced that it would optimize its resources to be consistent with a focus on Macrilen™-related efforts.
- Aeterna expects its monthly average use of cash in operations during the remainder of 2017 to range from \$1.7 million to \$1.9 million, down roughly 22% versus first quarter 2017.
- The Company looks forward to the potential from Macrilen™ on its path to becoming a successful specialty pharmaceutical company and expects to submit the Macrilen™ NDA in 3Q17 and, pending receipt of U.S. FDA approval, to commercially launch in 1Q18.
- Aeterna is actively pursuing additional portfolio opportunities via its product in-license/acquisition strategy. The Company’s leadership team has a strong track record of creating shareholder value.

Aeterna Zentaris

Aeterna Zentaris Inc.
 315 Sigma Drive, Suite 302D
 Charleston, SC 29483
 Phone: (843) 900-3223
 Fax: (843) 900-3250
www.aezsinc.com

AEZS One-Year Chart



Ticker (Exchange)	AEZS (NASDAQ)
Recent Price (05/15/17)	\$0.88 (NASDAQ)
52-week Range	\$0.78 - \$5.59
Shares Outstanding	~14.3 million
Market Capitalization	~\$12.6 million
Avg. 10-day Volume	1.2 mm
Insider Ownership + >5%	Less than 1%
EPS (Qtr. ended 03/31/17)	(\$0.31)
Employees	46

First Quarter 2017 Financial and Operating Results

Revenues

Revenues for the three months ended March 31, 2017 were \$261,000 versus \$242,000 for the same period in 2016. The increase is mainly due to the amortization of the up-front payment received in connection with one of the out-licensing agreements for Zoptrex™ that the Company entered into in 2016 with respect to a territory outside Aeterna's core areas of interest.

Research and Development (R&D) Costs

R&D costs for the three months ended March 31, 2017 were \$2.5 million versus \$3.7 million for the same period in 2016. The decrease is largely attributable to lower third-party costs from Zoptrex™, which is mainly resulting from the Company completing the clinical portion of the ZoptEC clinical trial during the 1Q17. Third-party costs attributable to Macrilen™ remained stable during the quarter versus the year-ago period.

General and Administrative (G&A) Expenses

G&A expenses were \$1.9 million for both three-month periods ended March 31, 2017 and 2016. G&A expenses remained stable and were in line with the Company's expectations for the first quarter.

Selling Expenses

Selling expenses for the three months ended March 31, 2017 were \$1.5 million versus \$1.7 million for the year-ago. Selling expenses for the three months ended March 31, 2017 and 2016 are mainly the costs of the Company's sales force related to the co-promotion activities along with its sales management team. The decrease in selling expenses is explained by the reduction in the number of sales representatives from 20 to 13 in February 2017.

Net Finance Income

Net finance income for the three months ended March 31, 2017 was \$1.5 million versus \$3.3 million for the year-ago period. The decrease in finance income is largely due to the change in fair value recorded in connection with the Company's warrant liability. Such change in fair value results from the periodic "mark-to-market" revaluation, via the application of option pricing models, of outstanding share purchase warrants. The closing price of Aeterna's common shares, which, on the NASDAQ, fluctuated from \$2.45 to \$3.65 during the three-month period ended March 31, 2017, compared to \$2.67 to \$4.40 during the same period in 2016, also had a direct impact on the change in fair value of warrant liability.

Net Loss

Net loss for the three months ended March 31, 2017 was \$(4.1) million, or \$(0.31) per basic and diluted share versus a net loss of \$(3.7) million, or \$(0.37) per basic and diluted share for the same period in 2016. The increase in net loss for the three months ended March 31, 2017 versus the same period in 2016, is largely attributable to lower operating expenses offset by lower net finance income. The basic and diluted loss per share decreased because the number of shares outstanding increased following an offering completed in November 2016, as well as issuances under various ATM programs.

Liquidity

As of March 31, 2017, cash and cash equivalents were \$17.8 million versus \$22.0 million as of December 31, 2016. The decrease in cash and cash equivalents is due to the net cash used in operating activities and variations in components of the Company's working capital. The decrease, however, was partially offset by net proceeds generated by the issuance of common shares under the Company's various ATM programs. Aeterna believes that its current cash position is sufficient to fund operations until the assumed approval of Macrilen™ at year-end.

Recent Events

All amounts are in U.S. dollars unless otherwise noted.

- *On May 9, 2017, the Company announced results of the vote on directors held at its 2017 annual meeting of shareholders on May 9, 2017. Each of the director nominees proposed by management for election was elected as director, without a vote by ballot being conducted. The Company received proxies with regard to voting on the six directors nominated for election as set forth in the table below:*

Name of Nominee	Votes For	%	Votes Withheld	%
Michael Cardiff	706,745	75.06	234,809	24.94
David A. Dodd	754,297	80.11	187,257	19.89
Carolyn Egbert	729,161	77.44	212,393	22.56
Juergen Ernst	731,223	77.66	210,331	22.34
Gérard Limoges	707,611	75.15	233,943	24.85
Ken Newport	740,594	78.66	200,960	21.34

All other matters at the shareholders' meeting were also approved by shareholders.

- *On May 8, 2017, the Company reported financial and operating results for the first quarter ended March 31, 2017. Revenues were \$261,000 for the three months ended March 31, 2017 versus \$242,000 for the same period in 2016. Net loss for the three months ended March 31, 2017 was \$(4.1) million, or \$(0.31) per basic and diluted share versus a net loss of \$(3.7) million, or \$(0.37) per basic and diluted share, for the same period in 2016. The increase in net loss is largely attributable to lower operating expenses offset by lower net finance income. As well, on May 1, 2017, Aeterna reported that the ZoptEC (zoptarelin doxorubicin in endometrial cancer) Phase 3 study of Zoptrex™ in women with locally advanced, recurrent or metastatic endometrial cancer did not achieve its primary endpoint of demonstrating a statistically significant increase in the median period of overall survival of patients treated with Zoptrex™ when compared to patients treated with doxorubicin. Therefore, results of the study did not support regulatory approval of Zoptrex™. Based on this outcome, the Company announced that it did not anticipate conducting clinical trials with respect to any other indications of Zoptrex™. The Company's focus has now shifted entirely to filing its new drug application (NDA) for Macrilen™ and, if the product is approved, to its commercial launch as soon as possible. The Company expects to submit the Macrilen™ NDA in 3Q17 and, if the product receives year-end 2017 approval from the U.S. FDA, to commercially launch Macrilen™ 1Q18.*
- *On May 1, 2017, Aeterna announced that the ZoptEC Phase 3 clinical study of Zoptrex™ (zoptarelin doxorubicin) in women with locally advanced, recurrent or metastatic endometrial cancer did not achieve its primary endpoint of demonstrating a statistically significant increase in the median period of overall survival of patients treated with Zoptrex™ as compared to patients treated with doxorubicin. The median overall survival period for patients treated with Zoptrex™ was 10.9 months compared to 10.8 months for patients treated with doxorubicin. This result was not a statistically significant, clinically meaningful increase in overall survival and as a result, the ZoptEC Phase 3 clinical study did not meet its primary endpoint. As well, Zoptrex™ generally performed no better than the comparator drug with respect to the secondary efficacy endpoints. For example, the median period of progression-free survival of the patients in the Zoptrex™ arm of the study was identical to that for patients in the doxorubicin arm. Lastly, there was no meaningful difference between the two arms with respect to safety; the number of patients with cardiac disorders was similar (eight in the Zoptrex™ arm and nine in the doxorubicin arm). As a result, the results of the study were not supportive to pursue regulatory approval.*

- *On April 27, 2017*, Aeterna announced that it had entered into a new At Market Issuance (ATM) Sales Agreement, dated April 27, 2017, with H.C. Wainwright & Co., LLC and that it has filed with the Securities and Exchange Commission a prospectus supplement related to sales and distributions of up to a maximum of 2,240,000 Common Shares through “at-the-market” issuances on the NASDAQ Stock Market, up to an aggregate amount of \$6,944,000 under the New ATM Sales Agreement. Wainwright will act as sales agent for any sales made under the new ATM program. The Common Shares will be sold at market prices prevailing at the time of the sale of the Common Shares, and, as a result, prices may vary. The New Sales Agreement and the Prospectus Supplement supersede and replace the Company’s prior At Market Issuance Sales Agreement entered into in April 2016 as well as its recently filed prospectus supplement dated March 28, 2017. Since April 1, 2016, the Company has issued approximately 2.3 million Common Shares and raised gross proceeds of approximately \$7.8 million under its previous Sales Agreement with Wainwright, of which approximately 600,000 Common Shares raising gross proceeds of approximately \$1.8 million were issued and sold under the March 28, 2017 prospectus supplement.
- *On April 3, 2017*, Aeterna announced that it has mailed a Notice of Meeting and Management Information Circular to the shareholders of record as of March 20, 2017 in connection with its Annual Meeting of shareholders to be held at the offices of Norton Rose Fulbright Canada, 1 Place Ville-Marie, Suite 2500, in Montreal, Canada on Tuesday, May 9, 2017 at 10:00 a.m. (Eastern Time). The Meeting Materials can be found at www.aezsinc.com or on the Company’s SEDAR profile at www.sedar.com.
- *On March 30, 2017*, Aeterna announced that following its meeting with the U.S. FDA on March 29, 2017, the Company intends to file a NDA seeking approval of Macrilen™ (macimorelin) for the evaluation of growth hormone deficiency (AGHD) in adults. During the Company’s meeting with the FDA, the Agency stated that the clinical studies performed by Aeterna with respect to Macrilen™ had addressed the prior deficiencies mentioned in the November 2014 complete response letter. This paves the way for the Company’s re-submission of an NDA for Macrilen™, which the Company expects to file in early third quarter of this year. While indicating that Aeterna’s conclusions as they relate to the performance of Macrilen™ are review issues and are subject to an examination of the complete data set, the FDA indicated that the summary data that was submitted prior to the meeting appears to support the propositions the Company advanced. Of key importance was that the FDA specified the additional statistical analysis of existing data that would be required to further support Aeterna’s conclusions. The Company believes that it can provide those data in a compelling fashion and demonstrate that Macrilen™ is a repeatable test with adequate sensitivity and specificity.

Potential Milestone for 2017

Product Development

- *Macrilen™ (macimorilen): submit NDA in early 3Q17.* If approved, Macrilen™ will be the only FDA approved drug for assessing AGHD, a disorder which affects about 75,000 adults in the U.S., Canada, and Europe, and is mostly caused by damage to the pituitary gland. The drug is patented through 2027 and has been granted Orphan Drug Designation. There is significant market expansion opportunity for traumatic brain injury (TBI) patients at risk of developing AGHD. The Company currently has 13 sales reps and anticipates scaling up to approximately 30 following approval.
- During the recent FDA meeting, the Agency stated that the clinical studies performed by Aeterna with respect to Macrilen™ address the prior deficiencies cited in the November 2014 complete response letter. This conclusion puts in place the Company's ability to re-submit an NDA for the drug, which Aeterna has stated could be filed in early 3Q17. This announcement brings the Company closer to commercializing Macrilen™ in the U.S. beginning in 2018.

Business Development

- Establish geographic collaborations for Macrilen™ in non-U.S. territories

Commercialization: Build commercial value through field promotion of:

- *Apifyny®.* Apifyny® is the only non-PSA based blood test for evaluating the risk of prostate cancer. The Company has an exclusive U.S. promotion agreement with Armune BioScience on a commission basis. This is a large market opportunity with 20+ million PSA tests performed annually.
- *Saizen®.* Saizen® for growth hormone replacement therapy in children and adults via a needle-free delivery system, which is co-promoted with EMD Serono in the U.S. on a commission basis. The U.S. market opportunity is significant at \$1.6 billion.

Strategic Alliance Opportunities

- Continue to actively seek strategic alliances that will facilitate the building of a product portfolio of commercial stage products in the U.S., while establishing partnerships in non-U.S. territories

Macrilen™ NDA Targeted to Be Filed in Third Quarter of 2017

Aeterna announced on March 30, 2017 that following its meeting with the U.S. FDA on March 29, 2017, the Company intends to file a new drug application (NDA) seeking approval of Macrilen™ (macimorelin) for the evaluation of growth hormone deficiency (AGHD) in adults. The Agency stated during a meeting with the Company that the clinical studies performed by Aeterna with respect to Macrilen™ addressed the prior deficiencies mentioned in the November 2014 complete response letter—setting the stage for an expected re-submission of an NDA for Macrilen™ in the 3Q17.

Though indicating that the Company's conclusions as they related to the performance of Macrilen™ are review issues—subject to an examination of the complete data set—the FDA indicated that the summary data submitted prior to the meeting appears to support the propositions that it be advanced. Key was that the FDA specified the additional statistical analysis of existing data that would be required to further support Aeterna's conclusions. The Company has stated that it expects that it can provide those data in a compelling fashion and demonstrate that Macrilen™ is a robust, repeatable test, showing adequate sensitivity and specificity and that the performance of the product would be improved by utilizing a more appropriate cut-off point. The FDA is expected to thoroughly review all data provided by Aeterna with its NDA and, after doing so, make a decision regarding the approval of the product. Important to note, however, is that there can be no assurance of approval of any NDA. However, Aeterna has stated that it believes it to be one important step closer to the commercialization of Macrilen™ in the U.S.

About the Study

The confirmatory Phase 3 clinical study of Macrilen™, entitled *Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of AGHD in Comparison with the Insulin Tolerance Test (ITT)*, was designed as a two-way crossover study with the ITT as the benchmark comparator and involved some 26 sites in the U.S. and Europe. The trial involved 157 subjects, of whom 140 completed two evaluable tests for AGHD using both Macrilen™ and the ITT. Thirty-four of the patients were evaluated using Macrilen™ a second time to measure the repeatability of the result obtained using Macrilen™ as the evaluation method. The study population consisted of 115 patients who were suspected of having AGHD as a result of the presence of one or more symptoms or risk factors. This segment of the population included a range of patients from those considered at low risk of having AGHD to those considered at high risk. The study population also included 25 healthy subjects, who had no risk of having AGHD. Under the study protocol, the evaluation of AGHD with Macrilen™ will be considered successful if the lower bound of the two-sided 95% confidence interval (or lower bound of the one-sided 97.5% confidence interval) for the primary efficacy variables is 75% or higher for “percent negative agreement,” and 70% or higher for the “percent positive agreement.” Based on meetings with the FDA as well as the European Medicines Agency (EMA) and subsequent written scientific advice, the Company believes that if successful, that the study meets the FDA's and the EMA's study-design expectations allowing U.S. and European approval.

About Macrilen™ (macimorelin)

Macimorelin, a ghrelin agonist, is an orally-active small molecule that stimulates the secretion of growth hormone. Macimorelin has been granted orphan drug designation by the FDA for diagnosis of AGHD. The Company owns the worldwide rights to this patented compound and has significant patent protection left. The Company's U.S. composition of matter patent expires in 2022 and its U.S. utility patent runs through 2027. The Company proposes, subject to FDA approval, to market macimorelin under the tradename Macrilen™.

One of the major advantages of Macrilen™ in contrast to the ITT and the other tests that are intravenous intramuscular injections is convenience as Macrilen™ is administered orally, where side effects experienced in the clinical trial have been very minor, with one of the worst reported was bad taste. As well, Aeterna did not identify any particular population in which Macrilen™ would be contraindicated in contrast to, for example, the ITT.

About AGHD

AGHD affects approximately 75,000 adults across the U.S., Canada, and Europe. Growth hormone not only plays an important role in growth from childhood to adulthood, but also helps promote a hormonally-balanced health status. AGHD mostly results from damage to the pituitary gland. It is usually characterized by a reduction in bone mineral density, lean body mass, exercise capacity, and overall quality of life as well as an increase of cardiovascular risks.

Market Opportunity

The Company expects that approximately 40,000 confirmatory tests for AGHD will be conducted each year after the introduction of Macrilen™, representing the target market at the time of Macrilen™'s anticipated commercialization following FDA approval.

From a customer development perspective, there are roughly 2,500 endocrinologists conducting these tests, primarily working from one of 150 pituitary centers, 200 to 300 large hospitals, and 13 defense and veterans brain injury centers—the latter of which becomes increasingly important as the Company develops and further expands the market for AGHD testing. As a result, approximately 30 field representatives are anticipated be required to commercialize and develop Macrilen™—a relatively small field sales force and commercial investment in supporting its commercial development.

Noteworthy is that the current AGHD stimulatory test, including the gold standard insulin tolerance test (ITT) and the glucagon stimulation test (GST), are injectable, take three to five hours to complete, are associated with potentially dangerous adverse events, and offer questionable effectiveness in the case of the GST or repeatability in the case of the ITT. Further, as medical procedures, their administration varies from physician-to-physician with the stimulatory agents and test procedures not being subject to FDA approval, regulation, or oversight. In general, endocrinologists report a relatively high level of non-valuable ITT results, as well as inconsistency in results due to procedural administration issues.

The stimulatory test—be it the ITT or the GST—were developed in the 1960's, so they are quite legacy procedures and were the only thing that had been identified at that point that could provide meaningful information. This would be where a blood sample could be taken and evaluated to be able to determine, or at least classify, whether or not a patient was deficient or not with growth hormones. This is what has been done in the past, noting that there is a well-recognized inconsistency in this procedural approach.

Aeterna believes that a significant commercial opportunity exists to clearly differentiate Macrilen™ from currently available testing procedures, resulting in a potential value proposition that supports establishing Macrilen™ as the new preferred standard AGHD stimulatory test based upon meaningful clinical features from the Company's Phase 3 trial. These benefits include accuracy, reproducibility, potency, safety, convenience, FDA approval (upon receipt), and administered in a consistent manner. Aeterna believes that adoption will likely occur rather quickly, where Macrilen™ will become the new standard.

Resulting from the Macrilen™ profile reflected in the Phase 3 confirmatory trial, the Company believes the existing AGHD stimulatory test market will likely be a profitable, albeit, small commercial opportunity of approximately \$30 million to \$50 million annually. Significant market expansion opportunities could exist related to traumatic brain injury (TBI) and in pediatric growth hormone deficiency (should Macrilen™ subsequently be approved for the evaluation in pediatric populations). However, the initial focus will be on achieving successful trial and adoption of Macrilen™ relative to the 40,000 stimulatory test market in the U.S. that exists today.

Expansion Opportunities

The existing need for AGHD stimulatory testing based upon annual TBI hospital admissions and in conjunction with the existing guidance from the Endocrine Society has the potential to increase the annual number of stimulatory tests. However, the Company has stated that its focus upon commercialization will be on the existing market.

Competition

Importantly, there is no competitive selling in this space as the existing legacy test procedures are not FDA approved. As well, the Company is not aware of any alternative products in development for this indication. With the Macrilen™ patent extending to the end of 2027, Aeterna has been granted orphan drug status and is fully committed to the success of this product.

Company Background

Aeterna Zentaris Inc. (“Aeterna” or “the Company”) is a specialty biopharmaceutical company developing and commercializing novel pharmaceutical therapies. The Company is engaged in drug development as well as in promoting products for others. The Company recently completed Phase 3 studies of two internally developed compounds, with one compound, Macrilen™ (macimorelin), for the evaluation of Adult Growth Hormone Deficiency (AGHD), moving forward and slated to submit a NDA in early 3Q17. Aeterna is also focusing its business development efforts on acquiring licenses to products that are relevant to its therapeutic areas of focus. The Company intends to license out certain commercial rights of internally developed products to licensees in non-U.S. territories where such out-licensing would enable the Company to ensure development, registration, and launch of its product candidates. Aeterna’s goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of its product portfolio, achieving successful commercial presence and growth, while consistently delivering value to its shareholders, employees, and the medical providers and patients who will benefit from its products. As well, the Company currently co-promotes two products: Saizen® [somatotropin (rDNA origin) for injection], a recombinant human growth hormone supplement, on behalf of EMD Serono; and, Apifyny®, the first non-PSA blood test for use in evaluating and managing the risk of prostate cancer, on behalf of Armune Bioscience.

Key Corporation Information

The Company was incorporated on September 12, 1990, under the Canada Business Corporations Act (CBCA) and continues to be governed by the CBCA. On December 30, 2002, it acquired Zentaris AG, a biopharmaceutical company based in Frankfurt, Germany. Zentaris was a spin-off of Asta Medica GmbH, a former pharmaceutical company affiliated with Degussa AG. In May 2004, the Company’s name was changed to Aeterna Zentaris Inc. and on May 11, 2007, Zentaris GmbH was renamed Aeterna Zentaris GmbH. On October 2, 2012, Aeterna effected a 6-to-1 reverse stock split and on October 5, 2012, the common shares began trading on a consolidated and adjusted basis on both the NASDAQ and TSX. In November 2015, the Company performed another share consolidation at a ratio of 100-to-1.

The Company’s operational base is in Charleston, South Carolina, with offices also in Frankfurt, Germany. Aeterna trades on both NASDAQ and TSX under the ticker symbol AEZS. Its three wholly owned direct and indirect subsidiaries include Aeterna Zentaris GmbH (Germany); Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany; and Aeterna Zentaris, Inc., an entity incorporated in the State of Delaware.

Risks and Disclosures

This Quarterly Update has been prepared by Crystal Research Associates, LLC (CRA) based upon information provided by Aeterna. CRA has not independently verified such information. Some of the information in this Update relates to future events or future business and financial performance. Such statements constitute forward-looking information within the meaning of the Private Securities Litigation Act of 1995. Such statements can only be predictions and the actual events or results may differ from those discussed due to the risks described in Aeterna's statements in its public and investor materials as well as regulatory forms filed from time to time.

The content of this report with respect to Aeterna has been compiled primarily from information available to the public released by the Company through news releases, investor presentations, and other materials released from time to time. Aeterna is solely responsible for the accuracy of this information. Information as to other companies and information as to the prevalence of certain disease and of the use of certain treatment modalities has been prepared from publicly available information and has not been independently verified by Aeterna or CRA. Certain summaries of activities and outcomes have been condensed to aid the reader in gaining a general understanding. CRA assumes no responsibility to update the information contained in this report. In addition, CRA has been compensated by the Company in cash of thirty-nine thousand U.S. dollars for its services in creating the base report and updates.

Investors should carefully consider the risks and information about Aeterna's business, as described in Crystal Research Associates' Executive Informational Overview® (EIO) published on April 21, 2015, and Aeterna's regulatory filings. Investors should not interpret the order in which considerations are presented in filings as an indication of their relative importance. The risks and uncertainties overviewed in the EIO are not the only risks that the Company faces. Additional risks and uncertainties not presently known to Aeterna or that it currently believes to be immaterial may also adversely affect the Company's business. If any of such risks and uncertainties develops into an actual event, Aeterna's business, financial condition, and results of operations could be materially and adversely affected, and the trading price of the Company's shares could decline. This report is published solely for information purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any state. Past performance does not guarantee future performance. Additional information about Aeterna, as well as copies of this report, can be obtained by calling (843) 900-3223.



CRYSTAL

RESEARCH ASSOCIATES

————— FACTS WITHOUT FICTION —————

About Our Firm: For the past decade, Crystal Research Associates, LLC (www.crystalra.com) has successfully articulated the exceptional stories of small- and mid-cap companies to the Wall Street investor community. Our methods are well-established and diverse, from compiling and disseminating objective, factual information for both institutional and retail investor audiences to capitalizing on our expansive line of targeted distribution channels, which include industry-leading financial data and information providers. Our distribution efforts are accompanied by the use of prominent social media channels and by strategic and targeted appearances on national news programs and print media.

Crystal Research Associates is led by Wall Street veterans, Jeffrey Kraws and Karen Goldfarb. Together, Kraws and Goldfarb have built a unique business model, capitalizing on decades of experience as an award-winning sell-side analyst team to produce institutional-quality industry and market research in a manner that is easily understood by investors and consumers. Our firm's approach has been proven successful over the years as our products are published and available on Bloomberg, Thomson Reuters/First Call, Capital IQ, FactSet, Yahoo! Finance, and scores of other popular forums.

880 Third Avenue, 6th Floor, New York, NY 10022
Office: (212) 851-6685